Entyvio subcutaneous injection 108mg pen, from Takeda Pharmaceutical, contains vedolizumab (genetical recombination). This monoclonal antibody selectively targets the gut to reduce inflammation, treating moderate-to-severe ulcerative colitis and Crohn’s disease in adults. It is supplied as 108mg x 0.68mL x 1 kit with YJ code 2399405G2021.
Entyvio subcutaneous injection 108mg pen
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →